Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released February 11, 2020 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--German drugmaker Merck KGaA is planning to spend 250 million euro ($275 million) to build a new facility for biotech development and manufacturing for clinical studies at its Corsier-sur-Vevey site in Switzerland.
Located near the biotech commercial manufacturing operation at Corsier-sur-Vevey, the new Biotech Development Center is designed to "bridge together research and manufacturing." It will comprise a building with a total of 15,700 square meters of development space, to focus the work of a number of different company units employing 250 employees working on Merck's biotech R&D pipeline at different sites today. Last year, the company committed to spending 150 million euro ($166 million) at its other Swiss manufacturing site at Aubonne to expand capacity for its biotech medicines. The new building will be dedicated to flagship Merck biotech medicines, including fertility treatment Gonal-f, newly launched therapies such as cancer drug Bavencio and potential future products currently in clinical development such as cancer investigational treatment M7824 (bintrafusp alfa*).
"This investment in the Merck Biotech Development Center reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines," said Stefan Oschmann, chairman of the executive board and chief executive officer of Merck.
Belén Garijo, member of the executive board of merck and CEO Healthcare, added: "Our investment in this biotech development facility in Switzerland is strongly related to the growth and progression of our Healthcare pipeline, and our confidence in its future potential."
The planned Biotech Development Center will showcase Merck's science and technology across its three business sectors, including Life Sciences' process solutions for clinical manufacturing and pilot plant operations. Construction is expected to be completed in 2021 and will be fully operational by the end of 2022.
Merck has been investing heavily in Europe in recent years, in particular at its main Darmstadt headquarters in Germany with plans to invest 1 billion euro ($1.12 billion) there over the next six years. This includes the construction of a new membrane plant there. The company also agreed to extend the employment guarantee for 11,000 employees at Darmstadt until the end of 2025. For additional information, see April 9, 2019, article - Merck Agrees to $1 Billion Investment in Germany.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
Located near the biotech commercial manufacturing operation at Corsier-sur-Vevey, the new Biotech Development Center is designed to "bridge together research and manufacturing." It will comprise a building with a total of 15,700 square meters of development space, to focus the work of a number of different company units employing 250 employees working on Merck's biotech R&D pipeline at different sites today. Last year, the company committed to spending 150 million euro ($166 million) at its other Swiss manufacturing site at Aubonne to expand capacity for its biotech medicines. The new building will be dedicated to flagship Merck biotech medicines, including fertility treatment Gonal-f, newly launched therapies such as cancer drug Bavencio and potential future products currently in clinical development such as cancer investigational treatment M7824 (bintrafusp alfa*).
"This investment in the Merck Biotech Development Center reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines," said Stefan Oschmann, chairman of the executive board and chief executive officer of Merck.
Belén Garijo, member of the executive board of merck and CEO Healthcare, added: "Our investment in this biotech development facility in Switzerland is strongly related to the growth and progression of our Healthcare pipeline, and our confidence in its future potential."
The planned Biotech Development Center will showcase Merck's science and technology across its three business sectors, including Life Sciences' process solutions for clinical manufacturing and pilot plant operations. Construction is expected to be completed in 2021 and will be fully operational by the end of 2022.
Merck has been investing heavily in Europe in recent years, in particular at its main Darmstadt headquarters in Germany with plans to invest 1 billion euro ($1.12 billion) there over the next six years. This includes the construction of a new membrane plant there. The company also agreed to extend the employment guarantee for 11,000 employees at Darmstadt until the end of 2025. For additional information, see April 9, 2019, article - Merck Agrees to $1 Billion Investment in Germany.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
